More: Digestive Disease Week (DDW) 2008

DDW 2008: Highlights in Liver Disease CME

May 17 - 22, 2008, San Diego, California

Author Information and Disclosures

This activity is not sanctioned by, nor a part of, Digestive Disease Week. Conference news does not receive grant support and is produced independently.

Release Date: June 30, 2008; Valid for credit through June 30, 2009

Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of Digestive Disease Week. These materials and the related activity are not sanctioned by Digestive Disease Week or the commercial supporter of the conference and do not constitute an official part of that conference.

Copyright © 2008 Medscape.
Medscape
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Explore current and emerging concepts and strategies in the management and treatment of patients infected with the hepatitis B virus, including issues in viral resistance
  2. Discuss current trends in the management of patients with hepatitis C, with a focus on new therapies on the horizon and a view toward the importance of predicting response to therapy
  3. Review the current state of the field regarding prevalence, screening, diagnosis, natural history, pathophysiology, and treatment of nonalcoholic fatty liver disease
Authors and Disclosures

Tram T. Tran, MD
Disclosure: Tram T. Tran, MD, has disclosed that she has received grants for clinical research from Bristol-Myers Squibb, Gilead, Idenix/Novartis, and Schering-Plough. Dr. Tran has also disclosed that she has received grants for educational activities from Bristol-Myers Squibb, Gilead, Idenix/Novartis, and Schering-Plough. Dr. Tran has also disclosed that she has served as an advisor or consultant to Bristol-Myers Squibb, Gilead, Idenix/Novartis, and Schering-Plough. Dr. Tran has also disclosed that she has served as a speaker for Bristol-Myers Squibb, Gilead, Idenix/Novartis, and Schering-Plough.


William F. Balistreri, MD
Disclosure: William F. Balistreri, MD, has disclosed no relevant financial relationships.


Maria L. Gaiso, PhD
Disclosure: Maria L. Gaiso, PhD, has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.